LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Endologix Inc. (“Endologix” or the “Company”) (Nasdaq: ELGX) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at email@example.com.
On August 2, 2016, CEO John McDermott stated that Endologix would seek approval of the original version of the Nellix system that was used in the Nellix investigational device exemption (“IDE”) clinical trial, the EVAS FORWARD-IDE Study, given since Endologix had the needed clinical data. On November 16, 2016, Endologix announced that the U.S. Food & Drug Administration requested two-year follow-up data on patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. When this news was announced, the stock price of Endologix declined.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles, dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.